Document Detail


Intervention in acute myocardial infarction.
MedLine Citation:
PMID:  2956832     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The most critical substrate lacking in infarcting myocardium is oxygen and early reperfusion would appear to be the most promising approach to infarct reduction. The efficacy of thrombolytic therapy has been shown by an increase in the global ejection fraction assessed by angiography or gated blood pool techniques and also by a decrease of almost 50% in the radioisotope perfusion defect after 3 to 4 weeks. Functional results in a group of patients subdivided according to success of thrombolysis and plasma creatine kinase levels showed that, among patients with successful thrombolysis, those with the least ischemic damage had experienced shorter ischemic periods and had significantly more collateral vessels supplying the infarcting area. It is recommended that the ischemic period should not extend beyond 3 to 5 hours before therapy is begun. The combination of intravenous streptokinase followed by intracoronary streptokinase was found to lead to a significant shortening of the ischemic period when compared with intracoronary streptokinase alone. Reocclusion of the infarct vessel has been shown to occur in 10% to 30% of patients after successful reperfusion, especially in arteries with severe residual stenosis, but immediate revascularization carried out after reperfusion in such patients can bring about a substantial decrease in the 1 year mortality rate. Successful reperfusion showed particular benefit in patients with previous myocardial infarction in another area, in patients with large left ventricular perfusion defects and in patients with predominantly right ventricular infarction.
Authors:
W Kübler; G Schuler; F Schwarz
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The American journal of cardiology     Volume:  60     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  1987 Jul 
Date Detail:
Created Date:  1987-08-31     Completed Date:  1987-08-31     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  2A-5A     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angioplasty, Balloon
Creatine Kinase / blood
Fibrinolytic Agents / therapeutic use*
Heart / radionuclide imaging
Humans
Myocardial Infarction / drug therapy*,  therapy
Myocardial Revascularization
Plasminogen Activators / therapeutic use
Streptokinase / therapeutic use
Stroke Volume
Time Factors
Tissue Plasminogen Activator / therapeutic use
Urokinase-Type Plasminogen Activator / therapeutic use
Chemical
Reg. No./Substance:
0/Fibrinolytic Agents; EC 2.7.3.2/Creatine Kinase; EC 3.4.-/Streptokinase; EC 3.4.21.-/Plasminogen Activators; EC 3.4.21.68/Tissue Plasminogen Activator; EC 3.4.21.73/Urokinase-Type Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The effect of restricting the indications for lumbosacral spine radiography in patients with acute b...
Next Document:  Restenosis after arterial angioplasty: a hemorrheologic response to injury.